ALNYLAM PHARMACEUTICALS, INC.

Registrant on federal lobbying filings · filed 2025 to 2026

$0 Income reported

1 Clients represented

6 Filings counted

0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. It also reported $2,490,000 of in-house lobbying expenses, which is what a registrant files when it lobbies for itself. Everything on this page is grouped by the registrant's LDA id (401107875), not by name.

Clients 1

ALNYLAM PHARMACEUTICALS, INC. $2,490,000 6 filings

Lobbyists named 2

CURTIS RHYNE 6 filings · through 2026 Rep. Virginia Foxx (2008-2009), House Republican Study Committee (2009-2014), Rep. Richard Hudson (2014-2017), Rep. George Holding (2017-2020)
MARGARET HERMAN 1 filing · through 2026 Legislative Aide, Senator Mark Warner (June 2017-May 2019); Legislative Assistant, Rep. Mikie Sherrill (May 2019-Jan. 2020); Senior LA, Rep. Dan Kildee (Jan. 2…

A lobbyist who previously held a covered government position must disclose it. We flag the ones whose name resolves to a member of Congress and link the ones still in our roster. The revolving door collects them across every firm.

Reported by year 2 years

2026 $880,000 2 filings
2025 $1,610,000 4 filings

Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 6
SENATE 6

Recent filings 6 total

Q2

ALNYLAM PHARMACEUTICALS, INC.

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $450,000 expenses · posted Jul 20, 2026

View → Q1

ALNYLAM PHARMACEUTICALS, INC.

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $430,000 expenses · posted Apr 20, 2026

View → Q4

ALNYLAM PHARMACEUTICALS, INC.

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $390,000 expenses · posted Jan 20, 2026

View → Q3

ALNYLAM PHARMACEUTICALS, INC.

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $390,000 expenses · posted Oct 20, 2025

View → Q2

ALNYLAM PHARMACEUTICALS, INC.

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $390,000 expenses · posted Jul 20, 2025

View → Q1

ALNYLAM PHARMACEUTICALS, INC.

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $440,000 expenses · posted Apr 21, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.